103 related articles for article (PubMed ID: 11276367)
1. Urokinase-like plasminogen activator receptor expression on disseminated breast cancer cells.
Tögel F; Datta C; Badbaran A; Kröger N; Renges H; Gieseking F; Jänicke F; Zander AR; Krüger W
J Hematother Stem Cell Res; 2001 Feb; 10(1):141-5. PubMed ID: 11276367
[TBL] [Abstract][Full Text] [Related]
2. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.
Allgayer H; Heiss MM; Riesenberg R; Grützner KU; Tarabichi A; Babic R; Schildberg FW
Cancer Res; 1997 Apr; 57(7):1394-9. PubMed ID: 9102229
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.
Heiss MM; Simon EH; Beyer BC; Gruetzner KU; Tarabichi A; Babic R; Schildberg FW; Allgayer H
J Clin Oncol; 2002 Apr; 20(8):2005-16. PubMed ID: 11956259
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemical phenotyping of disseminated tumor cells in bone marrow by uPA receptor and CK18: investigation of sensitivity and specificity of an immunogold/alkaline phosphatase double staining protocol.
Allgayer H; Heiss MM; Riesenberg R; Babic R; Jauch KW; Schildberg FW
J Histochem Cytochem; 1997 Feb; 45(2):203-12. PubMed ID: 9016310
[TBL] [Abstract][Full Text] [Related]
6. Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients.
Pierga JY; Bonneton C; Magdelénat H; Vincent-Salomon A; Nos C; Boudou E; Pouillart P; Thiery JP; de Cremoux P
Int J Cancer; 2005 Mar; 114(2):291-8. PubMed ID: 15543615
[TBL] [Abstract][Full Text] [Related]
7. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
[TBL] [Abstract][Full Text] [Related]
8. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
9. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
10. Influence of preharvest tumor cell contamination in bone marrow or blood does not predict resultant tumor cell contamination of granulocyte colony-stimulating factor mobilized stem cells.
Krüger W; Kröger N; Tögel F; Badbaran A; Renges H; Gieseking F; Gutensohn K; Jänicke F; Zander AR
J Hematother Stem Cell Res; 2001 Apr; 10(2):303-7. PubMed ID: 11359677
[TBL] [Abstract][Full Text] [Related]
11. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer.
Solomayer EF; Diel IJ; Wallwiener D; Bode S; Meyberg G; Sillem M; Gollan C; Kramer MD; Krainick U; Bastert G
Br J Cancer; 1997; 76(6):812-8. PubMed ID: 9310251
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator system and breast cancer (Review).
Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
Dublin E; Hanby A; Patel NK; Liebman R; Barnes D
Am J Pathol; 2000 Oct; 157(4):1219-27. PubMed ID: 11021826
[TBL] [Abstract][Full Text] [Related]
15. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
16. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Swiercz R; Wolfe JD; Zaher A; Jankun J
Clin Cancer Res; 1998 Apr; 4(4):869-77. PubMed ID: 9563880
[TBL] [Abstract][Full Text] [Related]
17. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.
Balic M; Lin H; Young L; Hawes D; Giuliano A; McNamara G; Datar RH; Cote RJ
Clin Cancer Res; 2006 Oct; 12(19):5615-21. PubMed ID: 17020963
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
19. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
20. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]